TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04035187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fast itraconazole tablet
Description: 100mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fast itraconazole tablet
Description: 100mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fast itraconazole tablet
Description: 100mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fast itraconazole tablet
Description: 100mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: medium itraconazole tablet
Description: 100mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: medium itraconazole tablet
Description: 100mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: medium itraconazole tablet
Description: 100mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: medium itraconazole tablet
Description: 100mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: slow itraconazole tablet
Description: 100mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: slow itraconazole tablet
Description: 100mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: slow itraconazole tablet
Description: 100mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: slow itraconazole tablet
Description: 100mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral itraconazole solution
Description: 100mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral itraconazole solution
Description: 100mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral itraconazole solution
Description: 100mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral itraconazole solution
Description: 100mg dose
Study: NCT03954873

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Actrapid (insulin) for lowering plasma glucose
Study: NCT05920616

Intervention type: OTHER
Group type: OTHER
Intervention: Magnetic Resonance Imaging
Description: Completion of Magnetic Resonance Imaging of the brain, heart, lungs, and liver with and without contrast.

Intervention type: OTHER
Group type: OTHER
Intervention: Magnetic Resonance Imaging
Description: Completion of Magnetic Resonance Imaging of the brain, heart, lungs, and liver with and without contrast.

Intervention type: OTHER
Group type: OTHER
Intervention: Ultra-High Resolution Computed Tomography (CT) Scan
Description: Completion of a high resolution CT scan of the lungs and high resolution CT of the coronary arteries.

Intervention type: OTHER
Group type: OTHER
Intervention: Ultra-High Resolution Computed Tomography (CT) Scan
Description: Completion of a high resolution CT scan of the lungs and high resolution CT of the coronary arteries.
Study: NCT00472641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone/Geodon
Description: Ziprasidone/Geodon
Study: NCT03583866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan
Description: 7 days of Candesartan (16mg/day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 7 days of Placebo
Study: NCT02039570

Intervention type: OTHER
Intervention: Transvaginal scan
Description: transvaginal scan conducted using duplex ultrasonography
Study: NCT02662465

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser
Description: Patients who develop oral mucositis even after the prevention, will be divided into three groups for laser sessions with the purpose of treatment of oral mucositis. The group assignment obeyed severity of oral mucositis.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser
Description: Patients who develop oral mucositis even after the prevention, will be divided into three groups for laser sessions with the purpose of treatment of oral mucositis. The group assignment obeyed severity of oral mucositis.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser
Description: Patients who develop oral mucositis even after the prevention, will be divided into three groups for laser sessions with the purpose of treatment of oral mucositis. The group assignment obeyed severity of oral mucositis.
Study: NCT02631694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Intake of propranolol pill (40 milligram)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propranolol
Description: Intake of propranolol pill (40 milligram)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intake of placebo pill (40 milligram)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Carbon dioxide
Description: Inhalation of 35% carbon dioxide
Study: NCT03463876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR 1210+apatinib
Description: SHR-1210 200mg (3mg/kg for underweight patients) iv every 2 weeks;Apatinib,250 mg/day.
Study: NCT03103061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lexiscan
Description: Coronary vasodilator
Study: NCT02631694

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbon dioxide
Description: Inhalation of 35% carbon dioxide

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Compressed air
Description: Inhalation of air
Study: NCT00860977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valacyclovir
Description: oral valacyclovir 500mg twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Odourless placebo tablet identical to valacyclovir in appearance and taste, to be taken twice daily
Study: NCT01981369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Intravenous sedation with dexmedetomidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Intravenous sedation with propofol

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Infraclavicular block
Description: All patients will receive ultrasound guided infraclavicular block with the standard protocol of the Block Room in St. Joseph Hospital.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infraclavicular block
Description: All patients will receive ultrasound guided infraclavicular block with the standard protocol of the Block Room in St. Joseph Hospital.
Study: NCT02970201

Intervention type: OTHER
Group type: OTHER
Intervention: EpxDialysis
Description: The EpxDialysis intervention consists of automated SMS text or voice messages delivered to the patient's preferred phone number three times per week. These messages provide details about the subject's upcoming hemodialysis session, anticipatory guidance regarding clinically-concerning symptoms, as well as the option for direct call routing to the dialysis center for rescheduling sessions.

Intervention type: OTHER
Group type: OTHER
Intervention: EpxDialysis
Description: The EpxDialysis intervention consists of automated SMS text or voice messages delivered to the patient's preferred phone number three times per week. These messages provide details about the subject's upcoming hemodialysis session, anticipatory guidance regarding clinically-concerning symptoms, as well as the option for direct call routing to the dialysis center for rescheduling sessions.
Study: NCT02744937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: aspirin is continued by its regular dosing
Study: NCT02769871

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standardized smoking cessation counseling
Description: Standardized smoking cessation counseling will be provided at their initial interview. They will be provided pamphlets from the National Stroke Association and the American Heart Association regarding risk factor reduction. Packets will include general information on risks associated with smoking along with the benefits of cessation, and methods to quit. Pamphlets will include Life's Simple 7 (American Heart Association, 2014) and Be Smoke Free: Facts about Smoking and Stroke Risk (National Stroke Association, 2009). Counseling will be scripted and standardized to ensure similar language with all participants.
Study: NCT04419142

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total infrapatellar fat pad excision
Description: Exposure for total knee arthroplasty (TKA) commonly includes total excision of the infrapatellar fat pad (IPFP). The rationale behind this is to obtain improved access to the lateral tibial plateau allowing a more accurate bone cut, baseplate placement and easier management of soft tissue interposition in the bone and cement interface. However, there is growing concern that as the IPFP is a highly vascularized and innervated fibrous adipose tissue filling the anterior compartment of the knee, its complete excision may have a detrimental effect on knee biomechanics and ultimately, TKA outcome. The reason for this effect has been suggested to be patellar tendon (PT) scarring and shortening via ischemic contracture following impaired vascularization, maintenance and biological repair of the tendon.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial infrapatellar fat pad excision
Description: It has been suggested in the literature that partial infrapatellar fat pad excision instead of total excision would diminish the potential negative effect on patellar tendon and knee biomechanics. However, there is only limited data in the literature and choice of total/partial infrapatellar fat pad excision in TKA remains debatable.
Study: NCT03531502

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ventricular Tachycardia Ablation
Description: Ventricular Tachycardia Ablation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Therapy
Description: For the antiarrhythmic naïve patients, the attending physician may initiate therapy with sotalol or amiodarone. For patients already on therapy with sotalol or amiodarone, the attending physician may choose to either increase the dosage/ frequency of these medications and/or add mexiletine to the regimen. Other alterations to medical therapy, such as adjusting the dose of beta-blockers, calcium-channel blockers, anti-hypertensive, diuretic or anti-anginal medications may be performed at the discretion of the attending physician.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Non-Invasive Programmed Stimulation (NIPS)
Description: All patients will receive this procedure in attempt to induce ventricular tachycardia. The outcome of this procedure determines if a patient will be randomized.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-Invasive Programmed Stimulation (NIPS)
Description: All patients will receive this procedure in attempt to induce ventricular tachycardia. The outcome of this procedure determines if a patient will be randomized.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-Invasive Programmed Stimulation (NIPS)
Description: All patients will receive this procedure in attempt to induce ventricular tachycardia. The outcome of this procedure determines if a patient will be randomized.
Study: NCT02388256

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Points of Stomach 36 (ST36), Stomach 37 (ST37), Liver 3 (LR3), Large Intestine 11 (LI11), Large Intestine 4 (LI4), Spleen 6 (SP6), Spleen 4 (SP4) and Pericardium 6 (PC6) will be used. Electrical stimulation with alternating frequency of 2 to 100 Hz will be applied to the selected points (LI4 to LI11, ST36 to ST37, and bilateral SP6).~Rationale of acupuncture treatments will include both traditional theory of harmonizing gastrointestinal function and strengthening vital energy as well as modern experimental and clinical evidence of regulating gastrointestinal motility and other symptom managements. Treatments will be provided by qualified hospital staff (Korean medical doctors) with more than 10 years of clinical experience.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture
Description: Points of Stomach 36 (ST36), Stomach 37 (ST37), Liver 3 (LR3), Large Intestine 11 (LI11), Large Intestine 4 (LI4), Spleen 6 (SP6), Spleen 4 (SP4) and Pericardium 6 (PC6) will be used. Electrical stimulation with alternating frequency of 2 to 100 Hz will be applied to the selected points (LI4 to LI11, ST36 to ST37, and bilateral SP6).~Rationale of acupuncture treatments will include both traditional theory of harmonizing gastrointestinal function and strengthening vital energy as well as modern experimental and clinical evidence of regulating gastrointestinal motility and other symptom managements. Treatments will be provided by qualified hospital staff (Korean medical doctors) with more than 10 years of clinical experience.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: early recovery program after surgery
Description: An enhanced recovery program after surgery that was designed and is currently implemented by surgeons, anesthetists, dietitians, and nurses will be provided. The program includes preoperative education, early water/food intake, early mobilization, early removal of Foley catheter and drains, structured nursing care, and nutritional support.
Study: NCT02369159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peramivir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir
Study: NCT01932424

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pelorus 1500
Description: a bedside blood propofol measurement device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol 2% (Diprivan 2%, Astra Zeneca UK)
Study: NCT02990286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 500mg concentrate for solution for infusion. One course of IV rituximab consisting of a first infusion of 1000 mg (500 ml solution) rituximab (day 1 infusion), and a second infusion of 1000 mg (500 ml solution) rituximab two weeks later (day 15 infusion)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of Rituximab
Description: 500 ml of saline (0.9% sodium chloride) for infusion One course of intravenous placebo of rituximab consisting of a first infusion of 500 ml of saline (0.9% sodium chloride) infusion (day 1 infusion), and a second infusion of 500 ml of saline infusion two weeks later (day 15 infusion)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: Mycophenolate Mofetil 500mg film-coated tablets~1 gram twice daily on oral route of MMF (= 2 grams daily) for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Mycophenolate Mofetil 500mg film-coated tablets~1 gram twice daily on oral route of MMF (= 2 grams daily) for 6 months.
Study: NCT00975494

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00773110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20% Human albumin solution
Description: Priming of the cardiopulmonary bypass circuit with Hartmann's solution (1000 mL), 20% Human serum albumin(300 mL), 0.9% sodium chloride solution (200 mL) and heparin (10,000 IU)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gelofusin
Description: Priming of the cardiopulmonary bypass circuit with Hartmann's solution (1000 mL), Gelofusine (300 mL, 4% succinylated gelatin, a synthetic colloid) and heparin (10,000 IU)
Study: NCT02706548

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrative Medication Self Management (IMedS) Intervention
Description: Half of participants received a manualized 30-minute occupational therapy intervention, Integrative Medication Self-Management Intervention (IMedS). During IMedS, the interventionist and client progress through three steps in which the pair: 1) reflect on past performance of medication management, 2) set a medication goal, and 3) generate strategies to reach the goal. During strategy generation, the interventionist uses therapeutic use of self and motivational interviewing to help the client self-generate new medication management strategies, specifically addressing 1) altering the activity, 2) advocacy, 3) education, 4) assistive technology, 5) environmental modifications, and 6) securing timely refills.
Study: NCT01735994

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Weight
Description: Eating Disorder Prevention Program for Athletes
Study: NCT00800761

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferoxamine and Deferiprone
Description: comparison of two arms: the first one treated with deferoxamine subcutaneous vials,40 mg/kg,12 hours/die plus deferiprone tablets 75 mg/kg three times/die versus the second one treated with deferoxamine subcutaneous vials,40 mg/kg,12 hours/die

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferoxamine and Deferiprone
Description: comparison of two arms: the first one treated with deferoxamine subcutaneous vials,40 mg/kg,12 hours/die plus deferiprone tablets 75 mg/kg three times/die versus the second one treated with deferoxamine subcutaneous vials,40 mg/kg,12 hours/die
Study: NCT02706548

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care Educational Intervention
Description: The standard care educational intervention was a 30-minute pamphlet based educational session. In the standard care intervention group, participants and interventionist first reviewed the pamphlet, Managing Your Medicines: Our Guide to Effective Medication Management (American Heart Association \& American Stroke Association, 2013). Then, the interventionist engaged in active listening, where she asked open-ended questions about the participant's medication routines and provided simple reflections. For the standard care procedures, the interventionist was prohibited from providing affirmations, complex reflections, summaries, problem-solving, or suggesting any specific interventions.
Study: NCT00906750

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluMist
Description: FluMist is a live attenuated intranasal influenza vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated influenza vaccine
Description: Inactivated influenza vaccine
Study: NCT04556097

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Care Ecosystem
Description: The Care Ecosystem model uses a telephone-based intervention to support persons with dementia and their care partners, screening for common dementia-related problems and providing modular standardized support protocols and caregiver education. Specially trained health care navigators systematically identify needs and address health status, advance care planning, medication management and management of challenging behaviors. Health care navigators receive backup support from a nurse, social worker, dementia specialist, and pharmacist, and maintain close communication with the primary care provider of the persons with dementia.~This Care Ecosystem model will be adapted to augment the dementia care provided by experienced Integrated Care Management Program nurse care managers engaged in the care of high-risk, high-cost patients in a large health system.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care Ecosystem
Description: The Care Ecosystem model uses a telephone-based intervention to support persons with dementia and their care partners, screening for common dementia-related problems and providing modular standardized support protocols and caregiver education. Specially trained health care navigators systematically identify needs and address health status, advance care planning, medication management and management of challenging behaviors. Health care navigators receive backup support from a nurse, social worker, dementia specialist, and pharmacist, and maintain close communication with the primary care provider of the persons with dementia.~This Care Ecosystem model will be adapted to augment the dementia care provided by experienced Integrated Care Management Program nurse care managers engaged in the care of high-risk, high-cost patients in a large health system.
Study: NCT00800761

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferoxamine
Description: deferoxamine vials,40 mg/kg,12 hours/die
Study: NCT01173926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Each trial participant will receive one single dose of each trial product in varying order (NN5401, NN1250 and insulin aspart) on 3 separate dosing visits. The trial products will be administered subcutaneously (under the skin).
Study: NCT04048161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: The patients will be divided into two groups randomly. Tacrolimus dose: 0.05-0.10 mg/kg/day, BID. The concentration for tacrolimus is 5-10 ng/ml，then reduce the dosage of drugs to maintian the concentration for tacrolimus is \< 5ng/ml. Total duration : 1 year.~Steroid dose: 1.0-1.5 mg/kg, qod or 0.5-0.75 mg/kg/day, qd， then gradually taper the steroid to 5mg/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: The patients will be divided into two groups randomly. Mycophenolate Mofetil dose: 20\~30mg/kg/day，BID. The concentration for MPA-AUC is 30\~50 μg.h/ml，then reduce the dosage of drugs to maintian the concentration for MPA-AUC is ≤40 μg.h/ml. Total duration : 1 year.~Steroid dose: 1.0-1.5 mg/kg, qod or 0.5-0.75 mg/kg/day, qd， then gradually taper the steroid to 5mg/day.
Study: NCT00922935

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cresco
Description: Cresco components loading 10 days post surgery
Study: NCT01735994

Intervention type: OTHER
Group type: OTHER
Intervention: Brochure
Description: Brochure on the Female athlete triad
Study: NCT01173926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: Each trial participant will receive one single dose of each trial product in varying order (NN5401, NN1250 and insulin aspart) on 3 separate dosing visits. The trial products will be administered subcutaneously (under the skin).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Each trial participant will receive one single dose of each trial product in varying order (NN5401, NN1250 and insulin aspart) on 3 separate dosing visits. The trial products will be administered subcutaneously (under the skin).
Study: NCT03044912

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mirabegron
Description: To evaluate the efficacy and safety of Mirabegron 50 mg vs 25 mg in Taiwanese patients with overactive bladder syndrome
Study: NCT00922935

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cresco
Description: Cresco loading at 6-8 weeks post surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Straumann components
Description: Straumann components loading 6-8 weeks post surgery
Study: NCT03044912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: To evaluate the efficacy and safety of Mirabegron 50 mg vs 25 mg in Taiwanese patients with overactive bladder syndrome